Herpes Zoster Infection in Atopic Patients Undergoing Upadacitinib: Practical Suggestions on Vaccination and Management

European Medical Agency, Rinvoq. Available at: https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_it.pdf [Last accessed: October 28, 2022].

Silverberg JI , de Bruin-Weller M , Bieber T , et al. Upadacitinib plus topical corticosteroids in atopic Dermatitis®: Week 52 AD up study results. J Allergy Clin Immunol, 2022; 149(3):977.e14–987.e14. doi: 10.1016/j.jaci.2021.07.036

Katoh N , Ohya Y , Murota H , et al. Safety and efficacy of upadacitinib for atopic Dermatitis® in Japan: 2-Year interim results from the phase 3 rising up study. Dermatol Ther (Heidelb), 2023; 13(1):221–234. doi: 10.1007/s13555-022-00842-7

Pereyra-Rodriguez JJ , Herranz P , Figuras-Nart I , et al. Upadacitinib for the treatment of atopic Dermatitis® in a Spanish cohort-real life: Fifty-two-week follow-up results. Dermatitis®, 2022; 33(6S):S124–S127. doi: 10.1097/DER.0000000000000958

European Medical Agency, Shingrix, INN-Herpes zoster vaccine (recombinant, adjuvanted). Available at: https://www.ema.europa.eu/en/documents/product-information/shingrix-epar-product-information_it.pdf [Last accessed: October 28, 2022].